Turnaround Time of Comprehensive Genomic Profiling in Lung Cancer and Other Solid Tumors [0.03%]
肺癌及其他实体瘤全面基因组测序的 turnaround 时间
Adam H Fox,Rachel B Keller-Evans,Richard S P Huang et al.
Adam H Fox et al.
Purpose: Given the importance of timely comprehensive genomic profiling (CGP) for the treatment of cancer, this study aimed to provide generalizable estimates of turnaround time (TAT) for tissue-based CGP. Secondary aims ...
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline [0.03%]
实体瘤和淋巴瘤循环肿瘤DNA检测：ASCO指南
Christina M Lockwood,Hans J Messersmith,Annette S Kim et al.
Christina M Lockwood et al.
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guide...
Patient Perspectives on and Willingness to Pay for Navigation Services Billed Under Centers for Medicare & Medicaid Services Principal Illness Navigation Codes [0.03%]
患者对疾病导航服务付费及使用意愿的调查——基于美国联邦医疗保险和医疗救助中心疾病导航主要疾病编码的角度
Courtney P Williams,Jessica Shuey,Nicole L Henderson et al.
Courtney P Williams et al.
Purpose: In 2024, the Centers for Medicare & Medicaid Services (CMS) introduced Principal Illness Navigation (PIN) codes to provide provider reimbursement for patient navigation. However, a potential unintended consequenc...
Carlyn Rose Tan,Neha Korde,Hira Mian
Carlyn Rose Tan
The treatment landscape for relapsed/refractory multiple myeloma has been transformed by the approval of T-cell-redirecting bispecific antibodies (BsAbs) targeting B-cell maturation antigen (teclistamab, elranatamab, and linvoseltamab) and ...
High Cost of Cancer Medicines in the United States: Opportunities for Policy Reforms [0.03%]
美国高昂的癌症药品价格及政策改革机遇
Ariadna Tibau,Kerstin Noelle Vokinger,Aaron S Kesselheim et al.
Ariadna Tibau et al.
Evaluating the Diagnostic Performance of Clear Cell Likelihood Score in Predicting Clear Cell Renal Cell Carcinoma Among Patients Younger Than 50 Years [0.03%]
评估透明细胞可能性评分在预测
Alexander Abdollahzadeh,Reza Lahiji,Matthew Harris et al.
Alexander Abdollahzadeh et al.
Purpose: Clear cell likelihood score (ccLS) is a multiparametric magnetic resonance imaging (MRI)-based scoring tool developed to differentiate clear cell renal carcinoma (ccRCC) from other renal mass categories. Past val...
Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma [0.03%]
重新评估多柔比星治疗软组织肉瘤的传统观点
Jacob N Stein,Mark G Woodcock,Kevin Y Chen
Jacob N Stein
Target Trial Emulation of Second-Generation Versus First-Generation Tyrosine Kinase Inhibitors in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [0.03%]
二代与一代酪氨酸激酶抑制剂在成人费城染色体阳性急性淋巴细胞白血病中的靶向试验模拟研究
Xiaoyi Zhang,Hong-Jie Jhou,Hsin-Yu Chen et al.
Xiaoyi Zhang et al.
Purpose: Philadelphia chromosome-positive acute lymphoblastic leukemia accounts for approximately 20%-30% of adult acute lymphoblastic leukemia and remains associated with relapse despite imatinib-based therapy. We compar...
Oncologist-Advanced Practice Provider Dyad: A Roadmap for Creating Synergy and Better Patient Care [0.03%]
肿瘤学-高级实践提供者组合：创建协同作用和更好患者护理的路线图
Robin Zon,Doug Flora,John E Hennessy et al.
Robin Zon et al.
Kumar Shivam,Jessica Allen,Faisal Aljabrain et al.
Kumar Shivam et al.
Purpose: Breast cancer survivors (BCS) face a significantly higher risk of treatment-induced bone loss compared with the general population. Despite clinical guidelines, baseline bone mineral density (BMD) screening and i...